
Richard Goldberg
Jul 4, 2025, 18:50
Our Goal is to Expand the CRC Patient Population That Can Benefit from Immunotherapy-Based Cancer Treatments
Agenus shared on LinkedIn:
“As Agenus Chief Development Officer, Dr. Richard Goldberg explains, our goal is to expand the CRC patient population that can benefit from immunotherapy-based cancer treatments.
Learn more about immunotherapy on our website.”
Read more about Colorectal Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 4, 2025, 17:59
Jul 4, 2025, 17:47
Jul 4, 2025, 17:39
Jul 4, 2025, 17:39
Jul 4, 2025, 17:38
Jul 4, 2025, 17:16
Jul 4, 2025, 17:05
Jul 4, 2025, 16:55